The effect of SGLT-2 inhibitors on liver stiffness in patients with diabetes mellitus and heart failure: a Fibroscan study
Irish Journal of Medical Science, cilt.194, sa.5, ss.1581-1587, 2025 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 194 Sayı: 5
- Basım Tarihi: 2025
- Doi Numarası: 10.1007/s11845-025-04087-z
- Dergi Adı: Irish Journal of Medical Science
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE
- Sayfa Sayıları: ss.1581-1587
- Anahtar Kelimeler: Diabetes, Fibroscan, Heart failure, Liver stiffness
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Aim: Studies have shown an increase in liver stiffness (LS) by liver elastography in patients with type 2 diabetes mellitus (DM) and regression of LS in patients receiving SGLT-2 inhibitors (SGLT-2i). We aimed to investigate liver stiffness and related factors before and after treatment with SGLT-2i in patients with diabetes and heart failure. Methods: In our prospective and cross-sectional study, 237 patients with diabetes were included. Patients were divided into 3 groups according to the presence and status of heart failure. Patients were treated with SGLT-2i, and their pre- and post-treatment status was evaluated. LS measurements were performed with FibroScan® Mini 430 device (Echosens, France). Results: NT-proBNP levels decreased significantly in all groups, with the most pronounced reduction in the HFrEF group (p < 0.001). Liver stiffness (kPa) also improved significantly in all groups, with the greatest change observed in the HFrEF group (Δ = 2.11 ± 1.1 kPa, p < 0.001). Similarly, HbA1c levels showed marked reductions across all groups, with the highest improvement seen in the group without heart failure (Δ = 1.28 ± 0.63%, p < 0.001). Conclusion: Our findings reinforce the potential of SGLT-2i therapy to improve liver stiffness and related metabolic and cardiac parameters in diabetic patients, irrespective of heart failure status.